ARYx to Present at the Oppenheimer Annual Healthcare Conference

• Press Release
• Source: ARYx Therapeutics, Inc.
• On 8:00 am EDT, Friday October 30, 2009

FREMONT, Calif.--(BUSINESS WIRE)--ARYx Therapeutics, Inc. (NASDAQ:ARYX - News) today announced that it will present at the Oppenheimer 20^th Annual Healthcare Conference in New York on November 4, 2009 at 10:15 am Eastern. A live Webcast of the presentation, together with the presentation slides, may be accessed at the ARYx Website http://www.aryx.com. The presentation will be archived for 30 days following the presentation.

Related Quotes

Symbol	Price	Change
ARYX	2.50	0.00

{"s" : "aryx","k" : "c10,l10,p20,t10","o" : "","j" : ""}

ARYx’s presentation will include an update on: the company’s licensing efforts; the safety extension phase of the Phase 2/3 clinical trial EmbraceAC that tested the safety and efficacy of tecarfarin, an oral anticoagulant agent; the regulatory strategy for the development of tecarfarin following EmbraceAC; and, the recently announced corporate changes in personnel that prepares ARYx for those activities that will follow the out-licensing of budiodarone, an oral anti-arrhythmic agent for the treatment of atrial fibrillation.

About ARYx Therapeutics, Inc.

ARYx Therapeutics is a biopharmaceutical company focused on developing a portfolio of internally discovered products designed to eliminate known safety issues associated with well-established, commercially successful drugs. ARYx uses its RetroMetabolic Drug Design technology to design structurally unique molecules that retain the efficacy of these original drugs but are metabolized through a potentially safer pathway to avoid specific adverse side effects associated with these compounds. ARYx currently has four products in clinical development: an oral anti-arrhythmic agent for the treatment of atrial fibrillation, budiodarone (ATI-2042); a prokinetic agent for the treatment of various gastrointestinal disorders, ATI-7505; an oral anticoagulant agent for patients at risk for the formation of dangerous blood clots, tecarfarin (ATI-5923); and, an agent for the treatment of schizophrenia and other psychiatric disorders, ATI-9242. Please visit the ARYx Website at www.aryx.com for additional information.

ARYx Therapeutics, Inc.
David Nagler, 510-585-2200 ext. 211
Vice President Corporate Affairs
dnagler@aryx.com